PD-1 Landscape Evolves as Subcutaneous Use Grows and Biosimilars Approach Across Solid Tumors

Spherix Global Insights reports that US oncologists anticipate rapid biosimilar uptake, up to 50% of PD-1/PD-L1 eligible patients within the first year. The study also reveals growing use of subcutaneous PD-1 therapies and tumor-specific brand preferences. Keytruda (Merck) remains strongly preferred in NSCLC and melanoma, while Opdivo-based regimens are more balanced in RCC. Biosimilars, such as Amgen's ABP-243, are expected to be used more frequently than bio-originators once approved.